

# Yao-jun Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7062313/publications.pdf>

Version: 2024-02-01

123  
papers

5,136  
citations

101384

36  
h-index

106150

65  
g-index

125  
all docs

125  
docs citations

125  
times ranked

6632  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply. <i>Hepatology</i> , 2022, 75, 491-492.	3.6	0
2	Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2016-2029.	0.7	7
3	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 150-160.	0.8	137
4	ASO Visual Abstract: Comparison between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate/Advanced-Stage Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2032-2033.	0.7	1
5	High serum fibroblast growth factor 21 is associated with inferior hepatocellular carcinoma survival: A prospective cohort study. <i>Liver International</i> , 2022, 42, 663-673.	1.9	9
6	Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Viruses</i> , 2022, 14, 656.	1.5	6
7	The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. <i>International Journal of Hyperthermia</i> , 2022, 39, 688-696.	1.1	2
8	Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. <i>Radiology</i> , 2021, 298, 680-692.	3.6	23
9	Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 657-670.	1.8	12
10	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. <i>European Journal of Cancer</i> , 2021, 155, 85-96.	1.3	19
11	Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 548-559.	0.5	23
12	Serum Bioavailable, Rather Than Total, 25-OH-vitamin D Levels Are Associated With Hepatocellular Carcinoma Survival. <i>Hepatology</i> , 2020, 72, 169-182.	3.6	25
13	Prediagnostic dietary intakes of vitamin A and Î²-carotene are associated with hepatocellular-carcinoma survival. <i>Food and Function</i> , 2020, 11, 759-767.	2.1	12
14	LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. <i>Theranostics</i> , 2020, 10, 7527-7544.	4.6	26
15	Association between dietary patterns and prognosis of hepatocellular carcinoma in the Guangdong liver cancer cohort study. <i>Hepatology Research</i> , 2020, 50, 1164-1175.	1.8	7
16	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
17	Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1639.	1.3	22
18	&lt;p&gt;Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 337-345.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. <i>International Journal of Surgery</i> , 2020, 77, 15-21.	1.1	3
20	Tescalcin is an unfavorable prognosis factor that regulates cell proliferation and survival in hepatocellular carcinoma patients. <i>Cancer Communications</i> , 2020, 40, 355-369.	3.7	16
21	Serum choline is associated with hepatocellular carcinoma survival: a prospective cohort study. <i>Nutrition and Metabolism</i> , 2020, 17, 25.	1.3	9
22	Sorafenib as an adjuvant therapy for hepatocellular carcinoma with microvascular invasion after radical resection: A prospective multicenter nonrandomized controlled study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16685-e16685.	0.8	3
23	Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes. <i>Aging</i> , 2020, 12, 12187-12205.	1.4	13
24	Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16593-e16593.	0.8	2
25	&lt;p&gt;Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?&lt;/p&gt;. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 377-384.	1.8	5
26	Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial. <i>American Journal of Cancer Research</i> , 2020, 10, 1467-1476.	1.4	1
27	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. <i>Cancers</i> , 2019, 11, 1116.	1.7	17
28	Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2019, 8, e1652540.	2.1	55
29	CACYBP Enhances Cytoplasmic Retention of P27Kip1 to Promote Hepatocellular Carcinoma Progression in the Absence of RNF41 Mediated Degradation. <i>Theranostics</i> , 2019, 9, 8392-8408.	4.6	24
30	Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	15
31	MiRâ€139â€5p, miRâ€940 and miRâ€193aâ€5p inhibit the growth of hepatocellular carcinoma by targeting <i>SPOCK1</i>. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2475-2488.	1.6	79
32	Predictive factors for the benefit of tripleâ€drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4200-4213.	1.3	9
33	Serum folate concentrations at diagnosis are associated with hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort study. <i>British Journal of Nutrition</i> , 2019, 121, 1376-1388.	1.2	7
34	EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. , 2019, 7, 300.		114
35	Single-Port Laparoscopic Hepatectomy for Liver Tumor: Operative Steps (With Video). <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, e98-e101.	0.4	3
36	Serum copper and zinc levels at diagnosis and hepatocellular carcinoma survival in the Guangdong Liver Cancer Cohort. <i>International Journal of Cancer</i> , 2019, 144, 2823-2832.	2.3	61

#	ARTICLE	IF	CITATIONS
37	Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 824-839.	3.6	62
38	The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?. <i>Medical Science Monitor</i> , 2019, 25, 4941-4951.	0.5	5
39	Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2018, 1, e183213.	2.8	19
40	Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. <i>Journal of Cancer</i> , 2018, 9, 1745-1753.	1.2	14
41	A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5027-5035.	1.3	22
42	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. <i>Cancers</i> , 2018, 10, 378.	1.7	36
43	The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study. <i>Cancer Management and Research</i> , 2018, Volume 10, 599-611.	0.9	1
44	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1068-1077.e2.	0.2	19
45	High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis. <i>Cancer Biomarkers</i> , 2018, 22, 611-619.	0.8	9
46	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 80-88.	2.9	74
47	Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. <i>Clinical and Translational Oncology</i> , 2017, 19, 844-852.	1.2	33
48	Left jackknife position: a novel position for laparoscopic hepatectomy. <i>Chinese Journal of Cancer</i> , 2017, 36, 31.	4.9	6
49	Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study. <i>Scientific Reports</i> , 2017, 7, 679.	1.6	26
50	Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2522-2529.	0.7	13
51	Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2017, 8, 2992-3000.	1.2	40
52	Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. <i>Journal of Cancer</i> , 2017, 8, 2984-2991.	1.2	13
53	Identification of an 88-microRNA signature in whole blood for diagnosis of hepatocellular carcinoma and other chronic liver diseases. <i>Aging</i> , 2017, 9, 1565-1584.	1.4	17
54	The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2016, 7, 626-632.	1.2	51

#	ARTICLE	IF	CITATIONS
55	The Association between Dietary Vitamin A and Carotenes and the Risk of Primary Liver Cancer: A Caseâ€“Control Study. <i>Nutrients</i> , 2016, 8, 624.	1.7	22
56	Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Medicine (United States)</i> , 2016, 95, e3015.	0.4	94
57	MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. <i>Journal of Pathology</i> , 2016, 240, 450-460.	2.1	66
58	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. <i>Oncology Letters</i> , 2016, 11, 2987-2994.	0.8	30
59	Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. <i>Chinese Journal of Cancer</i> , 2016, 35, 25.	4.9	37
60	Expression of Pim-3 in colorectal cancer and its relationship with prognosis. <i>Tumor Biology</i> , 2016, 37, 9151-9156.	0.8	14
61	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. <i>Oncolimmunology</i> , 2016, 5, e1083671.	2.1	56
62	Radiofrequency Ablation Systems and Operating Mechanisms. , 2016, , 25-33.		1
63	Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. <i>Oncotarget</i> , 2016, 7, 27938-27945.	0.8	4
64	A Nomogram for Predicting the Benefit of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2015, 5, 9202.	1.6	22
65	A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2015, 5, 15263.	1.6	27
66	Preparation of carbon-coated iron nanofluid and its application in radiofrequency ablation. , 2015, 103, 908-914.		10
67	A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelialâ€“mesenchymal transitionâ€“independent manner. <i>Hepatology</i> , 2015, 62, 452-465.	3.6	159
68	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 24163-24177.	0.8	54
69	Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2015, 21, 5582.	1.4	25
70	Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. <i>Oncotarget</i> , 2015, 6, 15494-15509.	0.8	56
71	Impact of oral antiâ€“hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. <i>Chinese Journal of Cancer</i> , 2015, 34, 205-16.	4.9	17
72	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 63, 122-130.	1.8	101

#	ARTICLE	IF	CITATIONS
73	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. <i>Lancet Oncology</i> , 2015, 16, 804-815.	5.1	237
74	Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1151-1162.	1.2	46
75	Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1032-1039.	1.4	22
76	Long-term therapy with sorafenib is associated with pancreatic atrophy. <i>Journal of Surgical Research</i> , 2015, 199, 314-321.	0.8	10
77	EIF4EBP1 Overexpression Is Associated with Poor Survival and Disease Progression in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0117493.	1.1	27
78	A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 41339-41349.	0.8	79
79	Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. <i>American Journal of Cancer Research</i> , 2015, 5, 3311-24.	1.4	35
80	Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells. <i>PLoS ONE</i> , 2014, 9, e100814.	1.1	19
81	Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2014, 12, 273.	1.8	52
82	Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1047-1054.	0.4	18
83	The inflammation-based scores to predict prognosis of patients with hepatocellular carcinoma after hepatectomy. <i>Medical Oncology</i> , 2014, 31, 883.	1.2	48
84	High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. <i>World Journal of Surgical Oncology</i> , 2014, 12, 226.	0.8	9
85	Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. <i>Chinese Journal of Cancer</i> , 2014, 33, 259-266.	4.9	8
86	Radiofrequency Ablation Does Not Induce the Significant Increase of CD4+CD25+Foxp3+ Regulatory T Cells Compared with Surgical Resection in Hepal-6 Tumor Model. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 333-340.	1.0	9
87	The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. <i>Annals of Surgical Oncology</i> , 2013, 20, 4305-4311.	0.7	68
88	Novel Percutaneous Radiofrequency Ablation of Portal Vein Tumor Thrombus: Safety and Feasibility. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 245-248.	0.9	11
89	Family history of hepatocellular carcinoma is not associated with its patients' prognosis after hepatectomy. <i>World Journal of Surgical Oncology</i> , 2013, 11, 280.	0.8	2
90	Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: A retrospective study. <i>European Journal of Surgical Oncology</i> , 2013, 39, 865-872.	0.5	55

#	ARTICLE	IF	CITATIONS
91	Percutaneous microwave ablation of larger hepatocellular carcinoma. <i>Clinical Radiology</i> , 2013, 68, 21-26.	0.5	100
92	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. <i>Heart</i> , 2013, 99, 1267-1274.	1.2	36
93	A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1709-1719.	1.2	26
94	Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 426-432.	0.8	433
95	Radiofrequency ablation versus open hepatic resection for elderly patients (>=65 years) with very early or early hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 3812-3820.	2.0	47
96	Postoperative Neutrophil-to-Lymphocyte Ratio Change Predicts Survival of Patients with Small Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. <i>PLoS ONE</i> , 2013, 8, e58184.	1.1	108
97	Recurrent Hepatocellular Carcinoma Treated with Sequential Transcatheter Arterial Chemoembolization and RF Ablation versus RF Ablation Alone: A Prospective Randomized Trial. <i>Radiology</i> , 2012, 262, 689-700.	3.6	183
98	Radiofrequency Ablation versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas 2 cm or Smaller: A Retrospective Comparative Study. <i>Radiology</i> , 2012, 262, 1022-1033.	3.6	203
99	Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. <i>International Journal of Hyperthermia</i> , 2012, 28, 132-140.	1.1	33
100	High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. <i>Journal of Translational Medicine</i> , 2012, 10, 135.	1.8	48
101	The role of miR-10b in metastatic pancreatic ductal adenocarcinoma. <i>Surgery</i> , 2012, 152, 936-938.	1.0	7
102	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in management of pancreatic cystic tumors. <i>Nuclear Medicine and Biology</i> , 2012, 39, 982-985.	0.3	9
103	Tumor Infiltration in the Medial Resection Margin Predicts Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1875-1882.	0.9	50
104	Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: A meta-analysis. <i>Pancreatology</i> , 2012, 12, 227-233.	0.5	35
105	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. <i>Cancer</i> , 2012, 118, 4725-4736.	2.0	139
106	Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1063-1071.	1.2	56
107	Expert consensus on local ablation therapies for primary liver cancer. <i>Chinese Clinical Oncology</i> , 2012, 1, 11.	0.4	1
108	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Prospective Comparative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 413-420.	0.7	305

#	ARTICLE	IF	CITATIONS
109	Conformal radiofrequency ablation of hepatocellular carcinoma with a multiâ€pin bipolar system. <i>Journal of Surgical Oncology</i> , 2011, 103, 69-74.	0.8	9
110	Role of Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: Experience of a Cancer Center in China. <i>Oncology</i> , 2011, 81, 100-104.	0.9	8
111	Preoperative Levels of Serum Interleukin-6 in Patients with Hepatocellular Carcinoma. <i>Hepato-Gastroenterology</i> , 2011, 58, 1687-93.	0.5	22
112	Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. <i>Cancer Biology and Therapy</i> , 2010, 9, 903-907.	1.5	39
113	A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2010, 36, 257-263.	0.5	56
114	Radiofrequency ablation as first-line treatment for small solitary hepatocellular carcinoma: Long-term results. <i>European Journal of Surgical Oncology</i> , 2010, 36, 1054-1060.	0.5	50
115	Role of radiofrequency ablation in the treatment of small hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2010, 2, 146.	0.8	11
116	Efficacy of combining temperature- and power-controlled radiofrequency ablation for malignant liver tumors. <i>Chinese Journal of Cancer</i> , 2010, 29, 408-412.	4.9	6
117	Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Retrospective Study. <i>Annals of Surgical Oncology</i> , 2008, 15, 3484-3493.	0.7	112
118	Risk factors of survival after percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Surgical Oncology</i> , 2008, 17, 23-31.	0.8	33
119	Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. <i>European Journal of Surgical Oncology</i> , 2008, 34, 166-172.	0.5	36
120	Hepatocellular Carcinoma Treated with Radiofrequency Ablation with or without Ethanol Injection: A Prospective Randomized Trial. <i>Radiology</i> , 2007, 244, 599-607.	3.6	137
121	Development and Validation of Prognostic Nomograms for BCLC A Stage Hepatocellular Carcinoma Beyond Milan Criteria after Curative Resection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
122	The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	3
123	Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3